Back to top
more

QIAGEN (QGEN)

(Real Time Quote from BATS)

$47.96 USD

47.96
255,909

-0.40 (-0.83%)

Updated Aug 8, 2025 10:52 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (142 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

AnaptysBio (ANAB) Jumps: Stock Rises 7.7%

by Zacks Equity Research

AnaptysBio (ANAB) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Zacks Equity Research

IVERIC bio (ISEE) Catches Eye: Stock Jumps 6.8%

by Zacks Equity Research

IVERIC bio (ISEE) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Zacks Equity Research

NeoGenomics (NEO) Looks Good: Stock Adds 5.5% in Session

by Zacks Equity Research

NeoGenomics (NEO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Zacks Equity Research

Boston Scientific Gets a Boost From MedSurg Arm Amid Coronavirus

by Zacks Equity Research

Within Endoscopy, Boston Scientific (BSX) believes that business recovery started since June.

Zacks Equity Research

Passage Bio (PASG) Looks Good: Stock Adds 5.4% in Session

by Zacks Equity Research

Passage Bio (PASG) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Zacks Equity Research

Abbott's New Antibody Test Gets FDA's EUA, Test Suite Expands

by Zacks Equity Research

Abbott's (ABT) latest antibody test is expected to give a clearer picture of the rate of recovery post coronavirus infection.

Zacks Equity Research

Here's Why You Should Hold on to NuVasive (NUVA) Stock Now

by Zacks Equity Research

Investors are optimistic about NuVasive (NUVA) on continued momentum across several recently-launched products as well as potential in its U.S. Surgical Support business.

Zacks Equity Research

Bruker Rides on Nano and MALDI Launches Despite Margin Debacle

by Zacks Equity Research

Bruker (BRKR) has several Bruker NANO products that are being assembled and tested in Malaysia.

Zacks Equity Research

Abbott's Data From Interim Clinical Study of ID NOW Positive

by Zacks Equity Research

Abbott's (ABT) recent data from an interim clinical study on its ID NOW COVID-19 rapid test reflects the test's capacity to deliver effective, consistent and reliable performance.

Zacks Equity Research

Bio-Rad (BIO) Hits a New 52-Week High: What's Driving It?

by Zacks Equity Research

Bio-Rad (BIO) is optimistic about maintaining robust testing portfolio along with strength in its Life Sciences business.

Zacks Equity Research

Evelo Biosciences (EVLO) Looks Good: Stock Adds 5.9% in Session

by Zacks Equity Research

Evelo Biosciences (EVLO) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Zacks Equity Research

Five Prime (FPRX) Looks Good: Stock Adds 5.1% in Session

by Zacks Equity Research

Five Prime (FPRX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Zacks Equity Research

NuVasive's (NUVA) MaXcess Retractor Study Results Positive

by Zacks Equity Research

NuVasive's (NUVA) MaXcess retractor's ability to perform lateral surgery in various approaches, including prone position, is validated by favorable study outcome.

Zacks Equity Research

Has QIAGEN N.V. (QGEN) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (QGEN) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Medtronic Announces U.S. Launch of Adaptix, Expands Portfolio

by Zacks Equity Research

Medtronic (MDT) introduces fully-navigated titanium implant procedure in the United States with the launch of Adaptix Interbody System.

Zacks Equity Research

Verastem (VSTM) Jumps: Stock Rises 7.1%

by Zacks Equity Research

Verastem (VSTM) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Zacks Equity Research

Walgreens' Pharmacy International Arm Faces Coronavirus Woes

by Zacks Equity Research

Walgreens (WBA) expects the adverse impact of COVID-19 to continue in the fiscal fourth quarter.

Zacks Equity Research

Integra (IART) Preliminary Q3 Results Show Recovery in Sales

by Zacks Equity Research

Integra's (IART) sales improvement in the third quarter is broad-based across the major franchises as per preliminary statement.

Zacks Equity Research

Here's Why You Should Add NEOGEN (NEOG) to Your Portfolio Now

by Zacks Equity Research

Investors continue to be optimistic about NEOGEN (NEOG) on robust segmental and geographical growth.

Zacks Equity Research

FDA Amends Hologic's Aptima's EUA for Asymptomatic Testing

by Zacks Equity Research

The FDA's modified EUA for Hologic's (HOLX) Aptima SARS-CoV-2 assay includes testing of asymptomatic individuals and symptomatic pooling protocol to curb the spread of coronavirus.

Zacks Equity Research

Zacks.com featured highlights include: Stamps, QIAGEN, Owens & Minor, Flowers Foods and Lakeland Industries

by Zacks Equity Research

Zacks.com featured highlights include: Stamps, QIAGEN, Owens & Minor, Flowers Foods and Lakeland Industries

Urmimala Biswas headshot

Coronavirus Drives Testing Stocks: Is There Room for More Upside?

by Urmimala Biswas

Given the current testing requirements across the world, the diagnostic testing business for COVID-19 is rapidly evolving.

Zacks Equity Research

Here's Why You Should Add Globus Medical to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Globus Medical (GMED) on robust product uptake and prominent sales trend improvement since the second quarter.

Urmimala Biswas headshot

LabCorp Heat Extraction COVID-19 Test Method Gets FDA's EUA

by Urmimala Biswas

According to LabCorp (LH), this process traps viral particles, eliminating the need for RNA extraction reagents.

Zacks Equity Research

Align Technology Rides on Invisalign Amid Coronavirus Woes

by Zacks Equity Research

Align Technology's (ALGN) Invisalign clear aligner has been receiving positive feedback and holds huge long-term market potential.